Immutep Limited (IMMP) Stock

About Immutep Limited

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Immutep Limited is headquartered in AU.

Immutep Limited (IMMP) stock trades at $0.44 with a market capitalization of $64.36M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.94, reflecting a net loss over the last twelve months, price-to-book of 0.80, price-to-sales of 13.32. Over the past 52 weeks the stock has ranged between $0.29 and $3.53, and currently trades 87.5% below its 52-week high.

On profitability, Immutep Limited generates a return on equity (ROE) of -69.20% (negative, reflecting a net loss), return on capital employed of -122.41%, an operating margin of -2520.00%, a net profit margin of -1220.00%.

Official website: www.immutep.com

Immutep Limited by the numbers, 2016–2025

Between 2016 and 2025 Immutep Limited reported revenue of $0 rising to $5.0M. Compounded, revenue has grown -6.5% a year over five years, —% over three, 25.0% over the last twelve months. Net profit held roughly flat to $-61.0M.

Operating margin went from -35117.8% in 2016 to -2506.5% in 2025, a gain of 32611.3 percentage points. The most recent net margin is -1220.00%. On a trailing twelve-month basis to Dec '25, revenue is $13.0M and net profit $-127.0M.

Borrowings fell from $5.0M to $2.0M, cash on hand is $99.1M, cash from operations was $-62.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -33.9% over five years, and was -42.4% in the most recent year.

The share price itself has compounded at -34.4% a year over five years, -41.3% over three, -73.0% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Immutep Limited (IMMP) — frequently asked questions